NCT04223596 - Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2026

Conditions

Lung CancerNSCLCNSCLC Stage IIIBNSCLC Stage IV

Interventions

DRUG

Brigatinib

Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)

Trial Locations (15)

15006

Complejo Hospitalario de A Coruña, A Coruña

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28222

Hospital Puerta de Hierro, Madrid

29010

Hospital Regional Universitario de Málaga, Málaga

35016

Hospital Universitario Insular de Gran canaria, Las Palmas de Gran Canaria

37007

Hospital Clínico de Salamanca, Salamanca

46009

Hospital Universitari i Politécnic La Fe, Valencia

46014

Hospital General de Valencia, Valencia

48903

Hospital Universitario de Cruces, Barakaldo

07120

Hospital Son Espases, Palma de Mallorca

08916

ICO Badalona, Badalona

08908

ICO Hospitalet, L'Hospitalet de Llobregat

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

03010

Hospital General de Alicante, Alicante

08035

Hospital Vall Hebron, Barcelona

All Listed Sponsors

lead

Fundación GECP

OTHER